Your browser doesn't support javascript.
loading
An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.
Charles, Julie; Chaperot, Laurence; Hannani, Dalil; Bruder Costa, Juliana; Templier, Isabelle; Trabelsi, Sabiha; Gil, Hugo; Moisan, Anaick; Persoons, Virginie; Hegelhofer, Harald; Schir, Edith; Quesada, Jean-Louis; Mendoza, Christophe; Aspord, Caroline; Manches, Olivier; Coulie, Pierre G; Khammari, Amir; Dreno, Brigitte; Leccia, Marie-Thérèse; Plumas, Joel.
Afiliação
  • Charles J; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France.
  • Chaperot L; Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France.
  • Hannani D; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France.
  • Bruder Costa J; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.
  • Templier I; Immune checkpoint inhibitors, PDCline Pharma, Grenoble.
  • Trabelsi S; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France.
  • Gil H; Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France.
  • Moisan A; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.
  • Persoons V; Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France.
  • Hegelhofer H; Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France.
  • Schir E; Pathology Department, Institut de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France.
  • Quesada JL; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France.
  • Mendoza C; Cell Therapy and Engineering Unit, Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint Ismier, France.
  • Aspord C; Cell Therapy and Engineering Unit, Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint Ismier, France.
  • Manches O; Cell Therapy and Engineering Unit, Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint Ismier, France.
  • Coulie PG; Délégation à la Recherche Clinique et à l'Innovation, CHU Grenoble Alpes, Grenoble, France.
  • Khammari A; Centre d'investigation Clinique, CHU Grenoble Alpes, Grenoble, France.
  • Dreno B; Centre d'investigation Clinique, CHU Grenoble Alpes, Grenoble, France.
  • Leccia MT; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France.
  • Plumas J; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.
Oncoimmunology ; 9(1): 1738812, 2020.
Article em En | MEDLINE | ID: mdl-32313721
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Melanoma Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Melanoma Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article